Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan

BMC Palliative Care201918:45

https://doi.org/10.1186/s12904-019-0428-3

©  The Author(s). 2019

  • Received: 24 July 2018
  • Accepted: 20 May 2019
  • Published:
Open Peer Review reports

Abstract

Background

This study aimed to analyze the determinants of patients’ choice between palliative chemotherapy and best supportive care (BSC) and to investigate how this choice affects overall survival (OS) and length of hospitalization according to Eastern Cooperative Oncology Group (ECOG) performance status (PS).

Methods

An oncologist explained the palliative chemotherapy and BSC options to 129 patients with incurable cancer during their first consultation. Data on the ECOG PS, treatment decision, OS, and the length of hospitalization were retrospectively collected over 4 years.

Results

Patients with an ECOG PS of 0–2 chose palliative chemotherapy more often than those with an ECOG PS of 3–4 (P < 0.01). Patients with ≤70 years chose palliative chemotherapy more often than those with > 70 (P < 0.05). And patients with gastric cancer and colon cancer chose palliative chemotherapy more often than those with CUP (carcinoma of unknown primary) (P < 0.05, P < 0.05 respectively). Factors associated with a significantly poorer OS in an adjusted analysis included the ECOG PS and treatment decision (hazard ratios: 0.18 and 0.43; P < 0.001, P < 0.01 respectively). In patients with an ECOG PS of 0–2, palliative chemotherapy was not associated with a longer OS compared with BSC (median OS: 14.5 vs. 6.8 months, respectively; P = 0.144). In patients with an ECOG PS of 3–4, palliative chemotherapy resulted in a significant survival gain compared to with BSC (median OS: 3.8 vs. 1.4 months, respectively; P < 0.05). Strong positive correlations between OS and the length of hospitalization were observed in patients with an ECOG PS of 3–4 who underwent palliative chemotherapy (r2 = 0.683) and the length of hospitalization was approximately one-third of their OS.

Conclusions

The determinants for treatment choice were age, ECOG PS and type of cancer, not sex difference. Oncologists should explain to patients that OS and the length of hospitalization vary according to the ECOG PS when selecting between palliative chemotherapy and BSC.

Keywords

  • Best supportive care
  • Hospitalization
  • Palliative chemotherapy
  • Performance status
  • Quality of life

Background

In advanced cancer, the therapeutic goal of oncologists is not to achieve a cure, but rather to control symptoms, prevent complications, prolong survival, and maintain as high a quality of life (QOL) as possible [1]. A shorter length of hospitalization is preferable for the QOL of all patients and their families [2, 3]. Hospital-administrated chemotherapy is perceived to be more distressing than chemotherapy at home [4]. However, looking at the Japanese healthcare system from an international perspective, the average length of hospitalization is extremely long [5].

For patients with incurable cancer, best supportive care (BSC) not including palliative chemotherapy may be an important option in some cases [6]. Several studies have shown that palliative chemotherapy generally does not prolong survival in patients with a poor Eastern Cooperative Oncology Group (ECOG) performance status [7, 8]. The American Society of Clinical Oncology advocates withholding palliative chemotherapy in patients with solid tumors and an ECOG PS of 3–4 and recommends BSC instead [9, 10].

The approach to palliative chemotherapy differs considerably depending on the expertise and perspectives of the physician, and oncologists tend to select aggressive chemotherapy [11–14]. BSC is typically not recommended by oncologists if other treatment options are available, including phase I clinical trials [15]. For patients, BSC is often perceived as a negative choice (as “doing nothing”) [16]. Hence, patients typically prefer palliative chemotherapy based on the potential to live longer rather than maintaining QOL [17].

This study aimed to analyze the determinants of patients’ choice between palliative chemotherapy and BSC and to investigate how this choice affects overall survival (OS) and length of hospitalization according to the ECOG PS.

Methods

In the present study, we retrospectively evaluated 129 patients with incurable cancer who attended the Miyagi Cancer Center (Natori, Japan). Patients with specific malignancies (e.g., metastatic breast cancer or blood malignancies) who had the potential to achieve a significantly longer OS with palliative chemotherapy than with BSC were excluded from this study. Palliative radiation was not an option in the patients of this study.

The oncologist explained the benefits and limitations of palliative chemotherapy and BSC to all patients du ring their first consultation. The emphatic points of the explanation of the treatment options were as follows: (1) The aim of palliative chemotherapy is not to achieve a cure, (2) the adverse effects of palliative chemotherapy may reduce QOL and lead to hospitalization, (3) it is possible to have BSC whenever necessary, (4) all patients eventually have only BSC, (5) BSC can be administered at home, and (6) patients receive full support for symptom relief.

The present study collected data on the ECOG PS and treatment decision (palliative chemotherapy vs. BSC) between May 2013 and May 2014 and on the OS and length of hospitalization between May 2013 and May 2017.

Statistical analyses

Differences in treatment decisions according to age (≤70 years vs. > 70 years), sex, type of cancer, and ≤ ECOG PS (0–2 vs. 3–4) were evaluated using logistic regression analysis. A multivariate Cox regression analysis was performed to adjust for confounding factors of OS (age, sex, type of cancer, ECOG PS, and treatment decision). A two-tailed P value of < 0.05 was considered significant. OS curves were estimated using the Kaplan-Meier method and compared using the log-rank test. The correlation between OS and the length of hospitalization was examined using scatter plot analysis. Coefficient of determination: r2 ≥ 0.5 was considered strong correlation, 0.5 > r2 ≥ 0.1 was considered moderate correlation. All statistical analyses were performed using Statistical Package for the Social Sciences for Windows (software version 24; SPSS Inc., Chicago, IL, USA).

Results

As shown in Table 1, a total of 129 patients with gastric cancer, colon cancer, esophageal cancer, miscellaneous malignant tumors (pancreatic cancer, sarcoma, bile duct cancer, duodenal cancer, ureteral cancer, bladder cancer, and anal cancer), and carcinoma of unknown primary (CUP) were enrolled. The majority of patients had a good ECOG PS (ECOG PS 0–2 [n = 108] and ECOG PS 3–4 [n = 21]). In this study, 101(78.3%) patients had palliative chemotherapy and 28 (21.7%) patients had BSC. More patients with CUP preferred BSC compared with those with gastric cancer and colon cancer (palliative chemotherapy [BSC]: CUP, 1 [6] vs. gastric cancer, 46 [9]; colon cancer, 32 [5], respectively; P < 0.05, P < 0.05,). More patients aged > 70 years chose BSC compared with those aged ≤70 years (palliative chemotherapy [BSC]: 39 [17] vs. 62 [11], respectively; P < 0.05). More patients with an ECOG PS of 0–2 chose palliative chemotherapy compared with those with an ECOG PS of 3–4 (palliative chemotherapy [BSC]: 91 [17] vs. 10 [11], respectively; P < 0.01). Sex did not affect treatment decisions (P = 0.237). The ECOG PS of patients with CUP was poorer than that of patients with gastric cancer (ECOG PS 0–2 [3, 4]: 2 [5] vs. 49 [6], respectively; P < 0.05). [see Additional file 1].
Table 1

Multivariate logistic regression analysis of treatment choice in patients with incurable cancer

Variable

Palliative chemotherapy

BSC

 

OR (95%CI)

P-value

101 (78.3%)

28(21.7%)

129

  

Type of cancer

 Gastric ca.

46 (83.6%)

9 (16.4%)

55

18.88 (1.59–224.59)

< 0.05*

 Colon ca.

32 (86.5%)

5 (13.5%)

37

21.99 (1.74–277.45)

< 0.05*

 Esophageal ca.

13 (76.5%)

4 (23.5%)

17

13.55 (0.95–192.92)

0.054

 MMT

9 (69.2%)

4 (30.8%)

13

5.83 (0.41–83.02)

0.193

 CUP

1 (14.3%)

6 (85.7%)

7

1.00 (ref.)

 

Sex

 Female

28 (73.7%)

10 (26.3%)

38

0.53 (0.18–1.53)

0.237

 Male

73 (80.2%)

18 (19.8%)

91

1.00 (ref.)

 

Age(years)

  ≤ 70

62 (84.9%)

11 (15.1%)

73

3.32 (1.16–9.54)

< 0.05*

  > 70

39 (69.6%)

17 (30.4%)

56

1.00 (ref.)

 

ECOG PS

 0–2

91 (84.3%)

17 (15.7%)

108

4.99 (1.52–16.42)

< 0.01*

 3–4

10 (47.6%)

11 (52.4%)

21

1.00 (ref.)

 

*P < 0.05

Abbreviations: BSC best supportive care, CI confidence interval, CUP carcinoma of unknown primary, ECOG Eastern Cooperative Oncology Group, MMT miscellaneous malignant tumor, OR odds ratio, PS performance status, ref reference

An ECOG PS of 0–2 was significantly and indepen dently associated with a longer OS compared with an ECOG PS of 3–4 (hazard ratio [HR]: 0.18, 95.0% confidence interval [CI]: 0.10–0.34; P < 0.001). Palliative chemotherapy was significantly and independently associated with a longer OS compared with BSC (HR: 0.43, 95.0% CI: 0.24–0.79; P < 0.01). Colon and esophageal cancers were associated with a longer OS compared with gastric cancer (HR: 0.49, 95.0% CI: 0.30–0.82; P < 0.01 and HR: 0.41, 95.0% CI: 0.20–0.86; P < 0.05, respectively). Age, sex, and other types of cancer were not associated with a longer OS (Table 2).
Table 2

Multivariate Cox regression analysis

Variable

HR (95.0% CI)

P-value

Primary site of the malignancy

–

< 0.05*

 Colon ca. vs. gastric ca.

0.49 (0.30–0.82)

< 0.01*

 Esophageal ca. vs. gastric ca.

0.41 (0.20–0.86)

< 0.05*

 MMT vs. gastric ca.

0.61 (0.29–1.27)

0.186

 CUP vs. gastric ca.

0.69 (0.25–1.93)

0.476

Sex (male vs. female)

0.80 (0.50–1.29)

0.367

Age (> 70 vs. ≤70 years)

0.84 (0.54–1.32)

0.455

ECOG PS (0–2 vs. 3–4)

0.18 (0.10–0.34)

< 0.001*

Palliative chemotherapy vs. BSC

0.43 (0.24–0.79)

< 0.01*

*P < 0.05

Abbreviations: BSC best supportive care, CI confidence interval, CUP carcinoma of unknown primary, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, MMT miscellaneous malignant tumor, PS performance status

Patients with an ECOG PS of 0–2 who underwent palliative chemotherapy were not associated with a better outcome compared with those who received BSC (median OS: 14.5 vs. 6.8 months, respectively; P = 0.144) (Fig. 1). Among patients with an ECOG PS of 3–4, those who received palliative chemotherapy had a better outcome than those who received BSC (median OS: 3.8 vs. 1.4 months, respectively; P < 0.05) (Fig. 2). Patients with gastric cancer, ≤70, > 70, and male patients who underwent palliative chemotherapy were associated with a better outcome compared with those who received BSC (2.7 vs. 13.0 months, 1.6 vs. 14.2 months, 4.1 vs. 11.6 months and 2.5 vs. 12.2 months, respectively; P < 0.001, P < 0.05, P < 0.05, P < 0.001) [see Additional file 2].
Fig. 1
Fig. 1

Kaplan-Meier curves of the overall survival of patients with Eastern Cooperative Oncology Group performance status of 0–2

Fig. 2
Fig. 2

Kaplan-Meier curves of the overall survival of patients with Eastern Cooperative Oncology Group performance status of 3–4

The correlation between OS and the length of hospitalization was examined using scatter plot analysis in 98 patients who died before Dec. 2018. Among the patients with an ECOG PS of 0–2, a moderate correlation was observed between OS (x-axis) and the length of hospitalization (y-axis) (coefficient of determination: r2 = 0.110, y = 61.5 + 0.06x) in palliative chemotherapy, and no correlation in BSC (r2 = 5.003E-4, y = 43.6 + 0.01x) (Fig. 3). Conversely, we observed significant positive correlations among the patients with an ECOG PS of 3–4 who had undergone palliative chemotherapy (r2 = 0.683, y = 34.5 + 0.32x) and a moderate correlation among the patients with an ECOG PS of 3–4 who had undergone BSC (r2 = 0.257, y = 22.7 + 0.11x) (Fig. 4). The correlations between OS and the length of hospitalization were also examined in patients with type of cancer, sex and age. The number of patients without gastric cancer were insufficient for the analysis. Among the patients with gastric cancer, ≤70 years and male patients, the moderate correlations were observed in palliative chemotherapy and BSC. Among the patients with > 70 years, the moderate correlation was observed in BSC [see Additional file 3].
Fig. 3
Fig. 3

Correlation between overall survival and the length of hospitalization in patients with Eastern Cooperative Oncology Group performance status of 0–2

Fig. 4
Fig. 4

Correlation between overall survival and the length of hospitalization in patients with Eastern Cooperative Oncology Group performance status of 3–4

Discussion

The major strength of this study is that an oncologist has provided an in-depth explanation of the treatment options (palliative chemotherapy and BSC) to all patients with incurable cancer during their first consultation, precluding any individual preferences for treatment that the oncologist may have had. The oncologist described the median OS of palliative chemotherapy and BSC to all patients and explained the differences between the two treatment options. The determinants for treatment choice were age and ECOG PS. Specifically, older patients and those with poor ECOG PS had the tendency to undergo BSC. Sex difference and disease without carcinoma of unknown primary had no influence on treatment choice. The tendency of having poor ECOG PS might influence the choice of BSC in patients with carcinoma of unknown primary.

In total, 84% of patients with an ECOG PS of 0–2 chose palliative chemotherapy. The remaining 16% chose BSC because they were either concerned about the adverse effects of chemotherapy or had something that they wanted to accomplish. Only one patient with an ECOG PS of 0–2 who chose BSC changed their mind and later received oral anticancer chemotherapy. Almost half (48%) of the patients with an ECOG PS of 3–4 chose palliative chemotherapy.

Several studies [18, 19] have shown that patients with incurable cancer who received palliative chemotherapy tend to have a longer OS and improved QOL compared with those who received BSC. However, in this study, patients with an ECOG PS of 0–2 did not exhibit a significantly longer OS when they selected palliative chemotherapy over BSC. This may be explained by the fact that some cancers in patients with a good ECOG PS are slow-growing with BSC. Patients with an ECOG PS of 0–2 who chose BSC attended the hospital almost monthly but were not admitted until their general condition worsened. These patients did not experience a reduction in QOL at the beginning of their clinical course. Although patients with an ECOG PS of 3–4 who received palliative chemotherapy had a longer OS than those who received BSC, the increment of survival was small. The degrees of the prolongation of OS by palliative chemotherapy are varied by type of cancer, sex and age.

In this study, the correlation between OS and the length of hospitalization was moderate in patients who received palliative chemotherapy with an ECOG PS of 0–2. However, extension in the length of hospitalization was not also so compared with the extended degree of the OS. Conversely, patients with an ECOG PS of 3–4 exhibited a significant correlation between OS and the length of hospitalization for the patients with palliative chemotherapy. The length of hospitalization in patients with an ECOG PS of 3–4 who received palliative chemotherapy was approximately one-third of their OS. The extension in the length of hospitalization were not also so compared with the extended degree of the OS in patients with male, ≤70 years, > 70 years and gastric cancer who received palliative chemotherapy or BSC.

In principle, care for patients with advanced cancer should include an individual assessment of the patient’s condition and their requirements for treatment throughout the course of their illness. Age is the most important factor for oncologists in deciding whether to recommend palliative chemotherapy or BSC, followed by the patient’s wishes, the length of expected survival, and other factors. When making decisions-making in about cancer treatment, the oncologist should collaborate with the patient and their family members to reach a shared decision [20, 21]. A lower preference for participating in decision-making in patients with incurable cancer was shown to be associated with a stronger preference for palliative chemotherapy [22]. Several studies [23–25] have suggested that oncologists should explain end-of-life care, including BSC, to their patients to reduce aggressive care and increase patient satisfaction.

However, complications can arise in shared decision-making. Patient treatment decisions are influenced based on whether the oncologist emphasizes the positive or negative aspects of the treatment (e.g., survival gain or the probability of dying) [26]. Few oncologists explain to patients how OS can be prolonged in detail as this is often difficult to predict [27, 28]. It is also difficult for oncologists to propose BSC to their patients as it could be perceived as “bad news” [29]. One study reported that only 30% of patients received an explanation about BSC from their oncologists [30]. Shared decision-making is also difficult for patients with incurable cancer [31]. The cognitive function and judgment abilities of these patients typically decline due to aging. Only approximately 60% of patients with incurable cancer understood the purpose of palliative chemotherapy [32]. Therefore, it is often the oncologist who decides the treatment [33, 34].

Treatment for advanced cancer also varies depending on the healthcare environment/system and culture. Several studies have reported on the types of treatment that patients with incurable cancer receive, including intensive palliative chemotherapy and BSC [35, 36]. In Japan, patients with incurable cancer often receive aggressive treatment, including palliative chemotherapy, until the end of life [37].

It is also understood from a previous study that provision of palliative chemotherapy toward the end of life is associated with frequent hospital admissions and high cost [38].

The originality of this study was that we investigated how the choice between palliative chemotherapy and BSC in patients with incurable cancer at the beginning of their treatment affected the length of hospitalization according to the ECOG PS, although it was a single-institution experience.

This study has several limitations. We conducted a retrospective study as it was difficult to perform a randomized controlled trial of patients with incurable cancer who underwent palliative chemotherapy or BSC at the beginning of the treatment. In this study, determinants of patients’ choice we examined were only 4 factors, age, sex, cancer type and ECOG, therefore, more factors are needed for example, economic conditions, caregivers and the level of cognitive impairment. Typically, QOL is evaluated using a questionnaire. The most widely used measures of cancer-specific health-related QOL are the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [39] and Functional Assessment of Cancer Therapy-General [40]. However, it is difficult to administer a questionnaire, particularly in patients with a poor ECOG PS, because of their physical and/or mental condition. Hospitalization is regarded as one predictor of QOL [41], therefore, we used the length of hospitalization as a surrogate marker of QOL in this study. An objective evaluation of the QOL of patients with incurable cancer other than the length of hospitalization is needed in future investigations.

Conclusion

The determinants for treatment choice were age and ECOG PS and not sex difference. Oncologists should be required to explain how the choice between palliative chemotherapy and BSC affects OS and the length of hospitalization in patients with incurable cancer to achieve effective shared decision-making.

Notes

Abbreviations

BSC: 

Best supportive care

CUP: 

Carcinoma of unknown primary

ECOG: 

Eastern Cooperative Oncology Group

OS: 

Overall survival

PS: 

Performance status

QOL: 

Quality of life

Declarations

Acknowledgements

Not applicable.

Funding

Not applicable.

Authors’ contributions

All authors made substantial contribution to the conception and design of this study. Mainly, MS and KO collected medical data, and YM analyzed these data and drafted the manuscript. All authors revised it critically for important intellectual content and gave final approval of the version to be published.

Ethics approval and consent to participate

The approval by the ethics committee of Miyagi Cancer Center was obtained for this study.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

According to the local ethics policy for retrospective analysis of our own anonymized clinical data, the information of this study and a way of opt-out were indicated in a website and informed consent was obtained from all patients. Therefore, participants did not provide written or verbal consent, and this study was approved by the ethics committee of Miyagi Cancer Center. (Reference number: No.3, May 26, 2017).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medical Oncology, Miyagi Cancer Center, Nodayama 47-1, Medeshima, Natori, Japan

References

  1. Browner I, Carducci MA. Palliative chemotherapy: historical perspective, applications, and controversies. Semin Oncol. 2005;32(2):145–55.View ArticleGoogle Scholar
  2. Hosaka T, Aoki T, Watanabe T, Okuyama T, Kurosawa H. Comorbidity of depression among physically ill patients and its effect on the length of hospital stay. Psychiatry Clin Neuros. 1999;53(4):491–5.View ArticleGoogle Scholar
  3. Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003;21(6):1133–8.View ArticleGoogle Scholar
  4. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapySoc. Sci Med. 1992;35(12):1505–9.View ArticleGoogle Scholar
  5. Tsuji T. Health-care issues: Japan’s aging society and appropriate countermeasures. Jpn J Nurs Sci. 2007;4(2):71–3.View ArticleGoogle Scholar
  6. Leong SS, Toh CK, Lim WT, Lin X, Tan SB, Poon D, et al. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol. 2014;2(3):230–6.View ArticleGoogle Scholar
  7. Wheatley-Price P, Ali M, Balchin K, Spencer J, Fitzgibbon E, Cripps C. The role of palliative chemotherapy in hospitalized patients. Curr Oncol. 2014;21(4):187–92.View ArticleGoogle Scholar
  8. Crosara Teixeira M, Marques DF, Ferrari AC, Alves MF, Alex AK, Sabbaga J, et al. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. Clin Colorectal Cancer. 2015;14(1):52–7.View ArticleGoogle Scholar
  9. Peppercorn JM, Smith TJ, Helft PR, DeBono DJ, Berry SR, Wollins DS, et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011;29(6):755–60.View ArticleGoogle Scholar
  10. Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–24.View ArticleGoogle Scholar
  11. Laryionava K, Heßner P, Hiddemann W, Winkler EC. Framework for timing of the discussion about forgoing cancer-specific treatment based on a qualitative study with oncologists. Support Care Cancer. 2015;23(3):715–21.View ArticleGoogle Scholar
  12. Koedoot CG, De Haes JC, Heisterkamp SH, Bakker PJ, De Graeff A, De Haan RJ. Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol. 2002;20(17):3658–64.View ArticleGoogle Scholar
  13. Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, et al. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015;26(7):1440–16.View ArticleGoogle Scholar
  14. Koedoot CG, Oort FJ, de Haan RJ, Bakker PJ, de Graeff A, de Haes JC. The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are palliative chemotherapy and watchful-waiting. Eur J Cancer. 2004;40(2):225–35.View ArticleGoogle Scholar
  15. Casarett DJ, Karlawish JH, Henry MI, Hirschman KB. Must patients with advanced cancer choose between a phase I trial and hospice? Cancer. 2002;95(7):1601–4.View ArticleGoogle Scholar
  16. Charles C, Redko C, Whelan T, Gafni A, Reyno L. Doing nothing is no choice: lay constructions of treatment decision-making among women with early-stage breast cancer. Sociol Health Illn. 1998;20(1):75–95.View ArticleGoogle Scholar
  17. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronoson NK. Role of health-related quality of life in palliative chemotherapy treatment decisions. J Clin Oncol. 2002;20(4):1056–62.View ArticleGoogle Scholar
  18. Simmonds P. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer collaborative group. BMJ. 2000;321(7260):531–5.View ArticleGoogle Scholar
  19. Qi X, Liu Y, Wang W, Cai D, Li W, Hui J, et al. Management of advanced gastric cancer: an overview of major findings from meta-analysis. Oncotarget. 2016;7(47):78180–205.View ArticleGoogle Scholar
  20. Ziebland S, Chapple A, Evans J. Barriers to shared decisions in the most serious of cancers: a qualitative study of patients with pancreatic cancer treated in the UK. Health Expect. 2015;18(6):3302–12.View ArticleGoogle Scholar
  21. Bakitas M, Kryworuchko J, Matlock DD, Volandes AE. Palliative medicine and decision science: the critical need for a shared agenda to foster informed patient choice in serious illness. J Palliat Med. 2011;14(10):1109–16.View ArticleGoogle Scholar
  22. Koedoot CG, de Haan RJ, Stiggelbout AM, Stalmeier PF, de Graeff A, Bakker PJ, et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients’ treatment preference and choice. Br J Cancer. 2003;89(12):2219–26.View ArticleGoogle Scholar
  23. Mack JW, Cronin A, Keating NL, Taback N, Huskamp HA, Malin JL, et al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol. 2012;30(35):4387–95.View ArticleGoogle Scholar
  24. Wright AA, Zhang B, Ray A, Mack JW, Trice E, Balboni T, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300(14):1665–73.View ArticleGoogle Scholar
  25. Jackson VA, Mack J, Matsuyama R, Lakoma MD, Sullivan AM, Arnold RM, et al. A qualitative study of oncologists’ approaches to end-of-life care. J Palliat Med. 2008;11(6):893–906.View ArticleGoogle Scholar
  26. O’Connor AM. Effects of framing and level of probability on patients’ preferences for cancer chemotherapy. J Clin Epidemiol. 1989;42(2):119–26.View ArticleGoogle Scholar
  27. Audrey S, Abel J, Blazeby JM, Falk S, Campbell R. What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study. BMJ. 2008;337:a752.View ArticleGoogle Scholar
  28. Stone PC, Lund S. Predicting prognosis in patients with advanced cancer. Ann Oncol. 2007;18(6):971–6.View ArticleGoogle Scholar
  29. Baile WF, Lenzi R, Parker PA, Buckman R, Cohen L. Oncologists’ attitudes toward and practices in giving bad news: an exploratory study. J Clin Oncol. 2002;20(8):2189–96.View ArticleGoogle Scholar
  30. Gattellari M, Voigt KJ, Butow PN, Tattersall MH. When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol. 2002;20(2):503–13.View ArticleGoogle Scholar
  31. de Kort SJ, Pols J, Richel DJ, Koedoot N, Willems DL. Understanding palliative cancer chemotherapy: about shared decisions and shared trajectories. Health Care Anal. 2010;18(2):164–74.View ArticleGoogle Scholar
  32. Cassileth BR, Zupkis RV, Sutton-Smith K, March V. Informed consent – why are its goals imperfectly realized? N Engl J Med. 1980;302(16):896–900.View ArticleGoogle Scholar
  33. de Haes H, Koedoot N. Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns. 2003;50(1):43–9.View ArticleGoogle Scholar
  34. Keating NL, Beth Landrum M, Arora NK, Malin JL, Ganz PA, van Ryn M, et al. Cancer patients’ roles in treatment decisions: do characteristics of the decision influence roles? J Clin Oncol. 2010;28(28):4364–70.View ArticleGoogle Scholar
  35. Porter J, Earle C, Atzema C, Liu Y, Howell D, Seow H, et al. Initiation of chemotherapy in cancer patients with poor performance status: a population-based analysis. J Palliat Care. 2014;30(3):166–72.View ArticleGoogle Scholar
  36. Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol. 2011;29(12):1587–91.View ArticleGoogle Scholar
  37. Kashiwagi T. Truth telling and palliative medicine. Intern Med. 1999;38(2):190–2.View ArticleGoogle Scholar
  38. SmithTJ HBE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060–5.View ArticleGoogle Scholar
  39. EORTC Quality of Life Group. The EORTC QLQ-C30 Manuals, Reference Values and Bibliography [CD Rom]. Brussels: EORTC Quality of Life Unit; 2002.Google Scholar
  40. Functional Assessment of Cancer Therapy-General. https://www.facit.org/FACITOrg/Questionnaires.
  41. Mapes DL, Lopes AA, Satayathum SS, Mccullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis outcome and practice pattern study (DOPPS). Kidney Int. 2003;64(1):339–49.View ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement

BMC Palliative Care

ISSN: 1472-684X

Contact us